Show simple item record

dc.contributor.authorMonane, Mark
dc.contributor.authorBohn, Rhonda L.
dc.contributor.authorGurwitz, Jerry H.
dc.contributor.authorGlynn, Robert J.
dc.contributor.authorChoodnovskiy, Igor
dc.contributor.authorAvorn, Jerry
dc.date2022-08-11T08:09:21.000
dc.date.accessioned2022-08-23T16:27:30Z
dc.date.available2022-08-23T16:27:30Z
dc.date.issued1994-01-01
dc.date.submitted2009-09-29
dc.identifier.citationClin Pharmacol Ther. 1994 Jan;55(1):76-83.
dc.identifier.issn0009-9236
dc.identifier.pmid7905370
dc.identifier.pmid7905370
dc.identifier.urihttp://hdl.handle.net/20.500.14038/36801
dc.description.abstractOBJECTIVE: To determine the frequency of congestive heart failure and cardiac conduction disturbances in elderly patients treated with topical glaucoma medications. METHODS: These case-control studies were conducted among participants in the New Jersey Medicaid and Medicare program from 1986 to 1990. A total of 35,445 subjects (ages 65 to 99 years) were included in the congestive heart failure analysis, and 4278 subjects were included in the conduction disorder analysis. RESULTS: The frequency of initiation of congestive heart failure therapy, defined as the new use of digoxin or furosemide, was not increased for users of topical glaucoma medications. The frequency of pacemaker placement was also not increased for topical glaucoma medication users. Analyses were adjusted for age, race, gender, nursing home or hospital status, number of prescription medications, and selected medication exposures. Advanced age and heavy use of other prescription medications were associated with an increased likelihood of both cardiovascular outcomes. CONCLUSION: Major cardiovascular side effects did not occur at an increased rate among patients using topical beta-blockers or other glaucoma medications compared with control subjects. This population-based study places findings from case reports and small clinical trials in a broader context to help with clinical assessment of the risks and benefits of glaucoma therapy in the elderly.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7905370&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1038/clpt.1994.14
dc.subjectAdministration, Topical
dc.subjectAdrenergic beta-Antagonists
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCase-Control Studies
dc.subjectFemale
dc.subjectGlaucoma
dc.subjectHeart Conduction System
dc.subjectHeart Failure
dc.subjectHumans
dc.subjectMale
dc.subjectPharmacoepidemiology
dc.subjectRisk
dc.subjectHealth Services Research
dc.subjectMedicine and Health Sciences
dc.titleTopical glaucoma medications and cardiovascular risk in the elderly.
dc.typeJournal Article
dc.source.journaltitleClinical pharmacology and therapeutics
dc.source.volume55
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/meyers_pp/164
dc.identifier.contextkey1019658
html.description.abstract<p>OBJECTIVE: To determine the frequency of congestive heart failure and cardiac conduction disturbances in elderly patients treated with topical glaucoma medications. METHODS: These case-control studies were conducted among participants in the New Jersey Medicaid and Medicare program from 1986 to 1990. A total of 35,445 subjects (ages 65 to 99 years) were included in the congestive heart failure analysis, and 4278 subjects were included in the conduction disorder analysis. RESULTS: The frequency of initiation of congestive heart failure therapy, defined as the new use of digoxin or furosemide, was not increased for users of topical glaucoma medications. The frequency of pacemaker placement was also not increased for topical glaucoma medication users. Analyses were adjusted for age, race, gender, nursing home or hospital status, number of prescription medications, and selected medication exposures. Advanced age and heavy use of other prescription medications were associated with an increased likelihood of both cardiovascular outcomes. CONCLUSION: Major cardiovascular side effects did not occur at an increased rate among patients using topical beta-blockers or other glaucoma medications compared with control subjects. This population-based study places findings from case reports and small clinical trials in a broader context to help with clinical assessment of the risks and benefits of glaucoma therapy in the elderly.</p>
dc.identifier.submissionpathmeyers_pp/164
dc.contributor.departmentDepartment of Medicine, Division of Geriatric Medicine
dc.contributor.departmentMeyers Primary Care Institute


This item appears in the following Collection(s)

Show simple item record